Keyword: Bristol-Myers Squibb
BMS already cut 107 positions at the facility earlier this year, and plans to close it by year's end.
Tally another win for Bristol-Myers Squibb’s immunotherapy combination, this time in rare colon cancers.
P&G already has already bought one OTC unit from Big Pharma this year. But with BMS’s Upsa unit potentially up for sale, could it go for another?
Following similar moves by Novartis, Merck KGaA and Pfizer, BMS is reportedly looking to sell its French consumer health business for up to €1.5 billion.
Appeals judges in Missouri overturned a $55 million talc powder verdict against J&J after finding the state doesn't have jurisdiction.
BMS' Opdivo is finally under FDA consideration as a therapy for previously untreated lung cancer.
Opdivo is the first I-O drug approved in China; Dr. Reddy's faces Suboxone Film patent spat; former multinational pharma executives jump to Chinese startups.
With impressive new survival data in hand, Bristol-Myers Squibb and AbbVie could land a new indication for Empliciti.
Some investors supported resolutions asking for more info about the link between drug prices and executive pay.
Opdivo goes directly to the lucrative lung cancer market with its first nod in China, where nearly 800,000 new patients are diagnosed each year.